The significant but partial vascular barrier protective ability of AKB-9778 further highlights a crucial role of the angiopoietin–Tie axis in CM pathogenesis, as well as, suggests VE-PTP inhibition as a potential adjuvant therapeutic option for CM treatment. Here, PTPRB is linked to cutaneous mastocytosis.